LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Geschlossen

BrancheGesundheitswesen

11.37 -6.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.11

Max

11.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.4M

676K

Verkäufe

961K

18M

KGV

Branchendurchschnitt

48.528

110.024

EPS

-0.034

Dividendenrendite

0.48

Gewinnspanne

3.67

Angestellte

212

EBITDA

-3M

2.3M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+62.95% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.48%

2.26%

Nächstes Ergebnis

2. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-120M

248M

Vorheriger Eröffnungskurs

17.79

Vorheriger Schlusskurs

11.37

Nachrichtenstimmung

By Acuity

50%

50%

149 / 351 Ranking in Healthcare

Simulations Plus Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. Feb. 2026, 22:36 UTC

Ergebnisse

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. Feb. 2026, 22:32 UTC

Ergebnisse

Woodside Energy Fiscal Year Net Profit Falls 24%

23. Feb. 2026, 23:58 UTC

Market Talk
Ergebnisse

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. Feb. 2026, 23:58 UTC

Market Talk
Ergebnisse

Global Energy Roundup: Market Talk

23. Feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. Feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. Feb. 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

Crescent Capital Partners Owns 53% of ClearView Wealth

23. Feb. 2026, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. Feb. 2026, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. Feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. Feb. 2026, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. Feb. 2026, 23:39 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. Feb. 2026, 23:31 UTC

Ergebnisse

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. Feb. 2026, 23:31 UTC

Ergebnisse

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. Feb. 2026, 23:28 UTC

Ergebnisse

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. Feb. 2026, 23:28 UTC

Ergebnisse

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. Feb. 2026, 23:28 UTC

Ergebnisse

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. Feb. 2026, 23:27 UTC

Ergebnisse

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. Feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. Feb. 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. Feb. 2026, 22:31 UTC

Ergebnisse

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. Feb. 2026, 22:24 UTC

Ergebnisse

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy FY Underlying Ebitda A$700.9 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. Feb. 2026, 22:21 UTC

Ergebnisse

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. Feb. 2026, 22:21 UTC

Ergebnisse

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. Feb. 2026, 22:20 UTC

Ergebnisse

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer-Vergleich

Kursveränderung

Simulations Plus Inc Prognose

Kursziel

By TipRanks

62.95% Vorteil

12-Monats-Prognose

Durchschnitt 19 USD  62.95%

Hoch 19 USD

Tief 19 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Simulations Plus Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Stimmung

By Acuity

149 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat